Further selective validation demonstrated that Yixin Ningshen tablet might target EGFR, ERBB2, VGFR2, FGF1, ESR1, LOX15, PGH2, HMDH, ADRB1, and ADRB2 and thus promote heart regeneration, new vessels' formation and the blood supply of myocardial region, reduce cardiac output, oxygen demand, inflammation, and arteriosclerosis (promoting vasodilation and intraplaque neoangiogenesis, lowering blood lipid) for the treatment of CHD. This evidence concerns the gene EGFR and coronary artery disorder.